Your first Mounjaro pen is 0.25mg — here is what to expect

The pen arrives. You're wondering whether 0.25mg is even doing anything.

This is, genuinely, the question our prescribers hear most often in the first few weeks. Someone injects their first 0.25mg dose on a Monday morning, waits a week, and notices… not very much. No dramatic drop in appetite. Maybe a little queasiness on day two, maybe nothing at all. They wonder whether the pen is working or whether they have somehow been short-changed.

The honest answer is that 0.25mg is designed to produce exactly that underwhelming experience, at least on the weight-loss front. The licensed Mounjaro dose range runs from 2.5mg up to 15mg, and the 0.25mg step sits below the therapeutic band entirely. It exists to prime your gut-hormone receptors and reduce the chance of the nausea, vomiting and stomach cramps that hit harder when people jump straight to an active dose. Think of it as a running start rather than the race itself.

The NHS medicines page for tirzepatide confirms that treatment begins at this low starting dose and titrates upward, with the prescriber deciding pace based on how the patient tolerates each step. So if the first few weeks feel uneventful, that is, broadly speaking, the plan working.

What actually happens at 0.25mg, and when it might feel different from nothing

Even at 0.25mg, some people do notice a mild reduction in appetite, or find that they feel full after smaller portions. That response varies considerably between individuals and is not a reliable predictor of how well higher doses will work. What is more consistent is the side-effect pattern: gastrointestinal symptoms, including nausea, loose stools, burping and a general feeling of stomach unsettledness, tend to peak in the first day or two after each injection and then ease. Most people find they settle considerably by the end of the first four-week pen.

Injection-site reactions (a little redness or tenderness at the spot) are also reported. Rotating between your abdomen, thigh and upper arm helps. For precise storage and handling guidance, the Mounjaro patient information leaflet on the Electronic Medicines Compendium is the definitive reference, room-temperature windows and refrigeration requirements are set out there in full.

One thing worth knowing about timing: if you are starting treatment just before a bank holiday or planning to travel in the first month, flag it to your prescriber. The pen needs to stay refrigerated between doses, and a few days away without planning can disrupt the routine before it has even formed. It is a small practical detail that catches people off guard.

If you want to understand what stepping up to 1.25mg involves, that transition is the first real move into the therapeutic range, and the shift in how the medicine feels is usually noticeable, with our guide to the 1.25mg Mounjaro dose covering what to expect from that first full treatment step in detail. Some patients also ask about what reaching 6.25mg looks like further along the journey, which gives a useful sense of where the titration schedule can take you over time.

Who starts on 0.25mg, and what the prescriber is watching for

The short answer is: almost everyone beginning Mounjaro for weight management starts here, regardless of body weight or health history. The licensed eligibility criteria for Mounjaro as a weight-management medicine cover adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or type 2 diabetes. Lower BMI thresholds may apply for some ethnic backgrounds under UK guidance.

What the prescriber watches during the 0.25mg phase is tolerability, not weight change. Can you manage the GI symptoms? Are there any signs that the medicine is not suitable? If the four weeks go smoothly, the next clinical review will consider whether to move you to 2.5mg, the first dose in the therapeutic band. If side effects were significant, staying at 0.25mg for a second month is sometimes the right call, and our guide to 0.25 tirzepatide covers what a repeat month at this starting dose typically involves. That decision belongs to the prescriber, not the patient, and it is made based on what you report.

Mounjaro is a Black Triangle medicine, meaning it is under additional MHRA monitoring. That is standard for newer medicines and simply means the regulatory body is collecting extra safety data, it does not signal a concern about its use. If anything unexpected happens between doses, the support team can point you to the right clinical resource. You can also report any suspected side effects directly through the MHRA Yellow Card scheme.

If you are weighing up whether Mounjaro is the right medicine to start with, the weight-loss treatment overview sets out the full picture across the options available. And when you are ready to take the next step, check your eligibility with our prescribers, the consultation is free, and a real clinician reviews your information the same day.